Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F19%3A10381949" target="_blank" >RIV/00216208:11110/19:10381949 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11140/19:10381949 RIV/61989592:15110/19:73596545 RIV/00098892:_____/19:N0000186

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Q4bcojYfzP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Q4bcojYfzP</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2147/CMAR.S185352" target="_blank" >10.2147/CMAR.S185352</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

  • Popis výsledku v původním jazyce

    Background: The principal aim of this report was to study second primary malignant neoplasms (SMNs) in long-term survivors of pancreatic ductal adenocarcinoma (PDAC) with regard to the germline genetic background. Methods: A total of 118 PDAC patients after a curative-intent surgery who were treated between 2006 and 2011 were analyzed. Of the 22 patients surviving for more than five years, 6 went on to develope SMNs. A genetic analysis of 219 hereditary cancer-predisposition and candidate genes was performed by targeted next-generation sequencing (NGS) in germline DNA from 20 of these patients. Results: Of all the radically resected PDAC patients, 6 patients went on to develop SMNs, which accounted for 27% of the long-term survivors. The median time to diagnosis of SMNs, which that included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer and urinary bladder cancer, was 52.5 months. At the time of analysis, none of these patients had died as a result of PDAC progression. We identified four carriers of germline pathogenic mutations in 20 NGS-analyzed patients. One carrier of the CHEK2 mutation was found among four analyzed patients who developed SMNs. Of the remaining 16 long-term PDAC survivors, three patients (19%) carried germline mutation(s) in the MLH1+ATM, CHEK2, and RAD51D gene, respectively. Conclusion: This retrospective analysis indicates that SMNs in PDAC survivors are an important clinical problem and may be more common than has been acknowledged to be the case. In patients with good performance status, surgical therapy should be considered, as the SMNs often have a favorable prognosis.

  • Název v anglickém jazyce

    Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

  • Popis výsledku anglicky

    Background: The principal aim of this report was to study second primary malignant neoplasms (SMNs) in long-term survivors of pancreatic ductal adenocarcinoma (PDAC) with regard to the germline genetic background. Methods: A total of 118 PDAC patients after a curative-intent surgery who were treated between 2006 and 2011 were analyzed. Of the 22 patients surviving for more than five years, 6 went on to develope SMNs. A genetic analysis of 219 hereditary cancer-predisposition and candidate genes was performed by targeted next-generation sequencing (NGS) in germline DNA from 20 of these patients. Results: Of all the radically resected PDAC patients, 6 patients went on to develop SMNs, which accounted for 27% of the long-term survivors. The median time to diagnosis of SMNs, which that included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer and urinary bladder cancer, was 52.5 months. At the time of analysis, none of these patients had died as a result of PDAC progression. We identified four carriers of germline pathogenic mutations in 20 NGS-analyzed patients. One carrier of the CHEK2 mutation was found among four analyzed patients who developed SMNs. Of the remaining 16 long-term PDAC survivors, three patients (19%) carried germline mutation(s) in the MLH1+ATM, CHEK2, and RAD51D gene, respectively. Conclusion: This retrospective analysis indicates that SMNs in PDAC survivors are an important clinical problem and may be more common than has been acknowledged to be the case. In patients with good performance status, surgical therapy should be considered, as the SMNs often have a favorable prognosis.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30204 - Oncology

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Cancer Management and Research

  • ISSN

    1179-1322

  • e-ISSN

  • Svazek periodika

    11

  • Číslo periodika v rámci svazku

    January

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    11

  • Strana od-do

    599-609

  • Kód UT WoS článku

    000455427700002

  • EID výsledku v databázi Scopus

    2-s2.0-85060545014